CD4 Overview
Molecule Name
T-cell surface antigen CD4
Synonyms
CD4,CD4mut,LEU3
Drug Development Progress
Drugs in Clinical Trials25
Approved Drugs1
Highest Development StageApproved
Target Synonym
CD4mut，CD4 Antigens，T-cell surface antigen T4/Leu-3，T-cell surface glycoprotein CD4，CD4，CD4 Molecule，CD4 Antigen (P55)，CD4 Receptor，CD4 Antigen
Background
T-cell surface glycoprotein CD4 is also known as T-cell surface antigen T4/Leu-3. CD4 contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CD4 is accessory protein for MHC class-II antigen/T-cell receptor interaction. CD4 induces the aggregation of lipid rafts. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.
CD4 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Semzuvolimab | dB4; UB-421; mAb-B4 | Phase 3 Clinical | United Biomedical Inc | HIV Infections | Details |
| ITV 1(Nonindustrial source) | ITV-1 | Phase 3 Clinical | Immunotech Laboratories, Synexa Life Sciences | HIV Infections | Details |
| RB-0003 | RB-0003; BNT-111 | Phase 2 Clinical | Biontech Se, Tron | Melanoma | Details |
| VRC-01-LS | VRC-HIVMAB-080-00-AB; VRC-01-LS | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| VRC-07-523 | VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380 | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), Taimed Biologics Inc | Acquired Immunodeficiency Syndrome; HIV Infections; Sexually Transmitted Diseases, Viral | Details |
| GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck | Details |
| Tregalizumab | hB-F5; BT-061 | Phase 2 Clinical | Biotest Pharma Gmbh | Arthritis, Rheumatoid; Asthma; Drug Hypersensitivity; Psoriasis | Details |
| Lotivibart | VH-3810109; GSK-3810109-A; VH-109; N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB; GSK-3810109 | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| MR-001 | MR001; MR-001 | Phase 2 Clinical | Shenzhen Maijiarui Biotechnology Co Ltd | Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| IMCY-0141 | IMCY-0141 | Phase 2 Clinical | Imcyse Sa | Multiple Sclerosis, Relapsing-Remitting | Details |
| Autologous Regulatory Т-cell Therapy | Phase 2 Clinical | Institute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus | Scleroderma, Systemic | Details | |
| TMB-365 | TMB-365 | Phase 2 Clinical | Taimed Biologics Inc | HIV Infections | Details |
| CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene) | CD4CAR (Icell Gene) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd, Stony Brook University School Of Medicine, University Of Louisville | Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, T-Cell; Lymphoma, T-Cell | Details |
| T-allo-10 | T-allo-10 | Phase 1 Clinical | Stanford University | Graft vs Host Disease; Hematologic Diseases; Hodgkin Disease; Leukemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD4 CAR T-cell therapy (University of Pennsylvania) | CAR-C34ZFN | Phase 1 Clinical | University Of Pennsylvania | HIV Infections | Details |
| 10E8.4/iMab (Aaron Diamond AIDS Research Center) | TMB-370 | Phase 1 Clinical | Aaron Diamond Aids Research Center For The City Of New York, Inc | HIV Infections | Details |
| CD4CAR | ICG-122; CD4CAR | Phase 1 Clinical | iCell Gene Therapeutics LLC | Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Mycosis Fungoides; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| MazF gene therapy (Takara Bio) | Phase 1 Clinical | Takara Bio Inc | HIV Infections | Details | |
| CALRLong36 peptide (Herlev Hospital) | Phase 1 Clinical | Herlev Hospital | Myeloproliferative Disorders | Details | |
| VRC-HIVMAB060-00-AB | VRC-HIVMAB060-00-AB; VRC01 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| VRC-HIVMAB0115-00-AB | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| LM-49 | Phase 1 Clinical | Shanxi Medical University, Shanxi University Of Traditional Chinese Medicine | Diabetic Nephropathies | Details | |
| SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
| LB-1901 | LB1901; LB-1901 | Phase 1 Clinical | Leukemia, T-Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral | Details | |
| IT-1208 (Kyowa Hakko Kirin) | IT-1208 | Phase 1 Clinical | Kyowa Hakko Kirin Co Ltd | Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ibalizumab | Hu5A8; TMB-355; TNX-355; 5AB | Approved | Biogen Inc | 特罗格佐, Trogarzo | United States | HIV Infections | Theratechnologies Inc | 2018-03-06 | HIV Infections | Details |